索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]王娜,杨丽霞.细胞外基质金属蛋白酶诱导因子与心血管疾病[J].国际心血管病杂志,2024,06:356-359.
点击复制

细胞外基质金属蛋白酶诱导因子与心血管疾病(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2024年06期
页码:
356-359
栏目:
综述
出版日期:
2024-12-10

文章信息/Info

Title:
-
作者:
王娜; 杨丽霞
650032 昆明，中国人民解放军联勤保障部队第九二〇医院心血管内科
Author(s):
-
关键词:
细胞外基质金属蛋白酶诱导因子; 动脉粥样硬化; 急性心肌梗死; 心肌缺血再灌注损伤
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2024.06.008
文献标识码:
-
摘要:
细胞外基质金属蛋白酶诱导因子（EMMPRIN）属于免疫球蛋白超家族的单通道跨膜糖蛋白受体，表达于正常及炎症组织中，在生理及病理活动中发挥重要作用。研究发现EMMPRIN在动脉粥样硬化、心肌梗死、心肌再灌注损伤等心血管疾病中表达水平增加，对心血管疾病的发生和进展有着重要作用，EMMPRIN可能成为心血管疾病潜在的治疗靶点。
Abstract:
-

参考文献/References

[1] Kumar D, Vetrivel U, Parameswaran S, et al. Structural insights on druggable hotspots in CD147: a bull's eye view[J]. Life Sci, 2019, 224:76-87.
[2] von Ungern-Sternberg SNI, Zernecke A, Seizer P. Extracellular matrix metalloproteinase inducer EMMPRIN (CD147) in cardiovascular disease[J]. Int J Mol Sci, 2018, 19(2):507.
[3] Zhong FY, Zhao YC, Zhao CX, et al. The role of CD147 in pathological cardiac hypertrophy is regulated by glycosylation[J]. Oxid Med Cell Longev, 2022, 2022:6603296.
[4] Mahmoud AM, Ali MM. High glucose and advanced glycation end products induce CD147-mediated MMP activity in human adipocytes[J]. Cells, 2021, 10(8):2098.
[5] López-Acosta O, de Los Angeles Fortis-Barrera M, Barrios-Maya MA, et al. Reactive oxygen species from NADPH oxidase and mitochondria participate in the proliferation of aortic smooth muscle cells from a model of metabolic syndrome[J]. Oxid Med Cell Longev, 2018, 2018:5835072.
[6] GuindoletD, Gabison EE. Role of CD147 (EMMPRIN/basigin) in tissue remodeling[J]. Anat Rec (Hoboken), 2020, 303(6):1584-1589.
[7] Shi Y, Yan WH, Lin QY, et al. Icariin influences cardiac remodeling following myocardial infarction by regulating the CD147/MMP-9 pathway[J]. J Int Med Res, 2018, 46(6):2371-2385.
[8] Baron MA, Ferreira LRP, Teixeira PC, et al. Matrix metalloproteinase 2 and 9 enzymatic activities are selectively increased in the myocardium of chronic chagas disease cardiomyopathy patients: role of TIMPs[J]. Front Cell Infect Microbiol, 2022, 12:836242.
[9] Wang CP, Jin R, Zhu XL, et al. Function of CD147 in atherosclerosis and atherothrombosis[J]. J Cardiovasc Transl Res, 2015, 8(1):59-66.
[10] Kampf S, Micko A, Stojkovic S, et al. Elevated EMMPRIN serum levels indicate plaque vulnerability in patients with asymptomatic high grade carotid stenosis[J]. Eur J Vasc Endovasc Surg, 2023, 65(4):474-483.
[11] Heinzmann D, Noethel M, Ungern-Sternberg SV, et al. CD147 is a novel interaction partner of integrin αMβ2 mediating leukocyte and platelet adhesion[J]. Biomolecules, 2020, 10(4):541.
[12] Khodadi E. Platelet function in cardiovascular disease: activation of molecules and activation by molecules[J]. Cardiovasc Toxicol, 2020, 20(1):1-10.
[13] Kraemer BF, Borst O, Gehring EM, et al. PI3 kinase-dependent stimulation of platelet migration by stromal cell-derived factor 1 (SDF-1)[J]. J Mol Med (Berl), 2010, 88(12):1277-1288.
[14] Rosa A, Butt E, Hopper CP, et al. Cyclophilin a is not acetylated at lysine-82 and lysine-125 in resting and stimulated platelets[J]. Int J Mol Sci, 2022, 23(3):1469.
[15] Tsuda T, Imanishi M, Oogoshi M, et al. Rho-associated protein kinase and cyclophilin a are involved in inorganic phosphate-induced calcification signaling in vascular smooth muscle cells[J]. J Pharmacol Sci, 2020, 142(3):109-115.
[16] Li LY, Yang YY, Zhang HN, et al. Salidroside ameliorated intermittent hypoxia-aggravated endothelial barrier disruption and atherosclerosis via the cAMP/PKA/RhoA signaling pathway[J]. Front Pharmacol, 2021, 12:723922.
[17] Pahk K, Joung C, Song HY, et al. SP-8356, a novel inhibitor of CD147-cyclophilin A interactions, reduces plaque progression and stabilizes vulnerable plaques in apoE-deficient mice[J]. Int J Mol Sci, 2019, 21(1):95.
[18] Pahk K, Noh H, Joung C, et al. A novel CD147 inhibitor, SP-8356, reduces neointimal hyperplasia and arterial stiffness in a rat model of partial carotid artery ligation[J]. J Transl Med, 2019, 17(1):274.
[19] Ramírez-Carracedo R, Hernández I, Moreno-Gómez-Toledano R, et al. NOS3 prevents MMP-9, and MMP-13 induced extracellular matrix proteolytic degradation through specific microRNA-targeted expression of extracellular matrix metalloproteinase inducer in hypertension-related atherosclerosis[J]. J Hypertens, 2024, 42(4):685-693.
[20] An N, Zhang GX, Li YJ, et al. Promising antioxidative effect of berberine in cardiovascular diseases[J]. Front Pharmacol, 2022, 13:865353.
[21] Lu L, Huang JJ, Xue X, et al. Berberine regulated miR150-5p to inhibit P2X7 receptor, EMMPRIN and MMP-9 expression in oxLDL induced macrophages[J]. Front Pharmacol, 2021, 12:639558.
[22] Wang W. Correlation between extracellular matrix metalloproteinase inducer in peripheral blood and serum MMPs in patients with acute coronary syndrome[J]. Cell Mol Biol (Noisy-le-grand), 2022, 68(11):97-104.
[23] Seizer P, Fuchs C, Ungern-Sternberg SNIV, et al. Platelet-bound cyclophilin A in patients with stable coronary artery disease and acute myocardial infarction[J]. Platelets, 2016, 27(2):155-158.
[24] Huang CH, Chang CC, Kuo CL, et al. Decrease in plasma cyclophilin A concentration at 1 month after myocardial infarction predicts better left ventricular performance and synchronicity at 6 months: a pilot study in patients with ST elevation myocardial infarction[J]. Int J Biol Sci, 2015, 11(1):38-47.
[25] Akkus MN, Ormam A, Seyis S, et al. Plasma EMMPRIN levels in acute myocardial infarction and stable coronary artery disease[J]. Clin Invest Med, 2016, 39(3):E79-E87.
[26] Ramirez-Carracedo R, Sanmartin M, Ten A, et al. Theranostic contribution of extracellular matrix metalloprotease inducer-paramagnetic nanoparticles against acute myocardial infarction in a pig model of coronary ischemia-reperfusion[J]. Circ Cardiovasc Imaging, 2022, 15(6):e013379.
[27] Cuadrado I, Piedras MJGM, Herruzo I, et al. EMMPRIN-targeted magnetic nanoparticles for in vivo visualization and regression of acute myocardial infarction[J]. Theranostics, 2016, 6(4):545-557.
[28] Tarin C, Lavin B, Gomez M, et al. The extracellular matrix metalloproteinase inducer EMMPRIN is a target of nitric oxide in myocardial ischemia/reperfusion[J]. Free Radic Biol Med, 2011, 51(2):387-395.
[29] Hernandez I, Tesoro L, Ramirez-Carracedo R, et al. Ivabradine induces cardiac protection against myocardial infarction by preventing cyclophilin-A secretion in pigs under coronary ischemia/reperfusion[J]. Int J Mol Sci, 2021, 22(6):2902.
[30] Cuadrado I, Castejon B, Martin AM, et al. Nitric oxide induces cardiac protection by preventing extracellular matrix degradation through the complex caveolin-3/EMMPRIN in cardiac myocytes[J]. PLoS One, 2016, 11(9):e0162912.
[31] ?gren MS, Auf dem Keller U. Matrix metalloproteinases: how much can they do?[J]. Int J Mol Sci, 2020, 21(8):2678.
[32] Tesoro L, Ramirez-Carracedo R, Hernandez I, et al. Ivabradine induces cardiac protection by preventing cardiogenic shock-induced extracellular matrix degradation[J]. Rev Esp Cardiol (Engl Ed), 2021, 74(12):1062-1071.

备注/Memo

备注/Memo:
通信作者：杨丽霞，E-mail：doctorlixia@aliyun.com
更新日期/Last Update: 2024-12-10